Developments in chemotherapy of breast cancer

Cancer

Volumn 88, Issue 12 SUPPL., 2000, Pages 3073-3079

  Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast carcinoma; Cytotoxic drugs; HER 2 neu oncoprotein; Taxanes; Trastuzumab

Indexed keywords

5 ETHYNYLURACIL; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC ANTIBIOTIC; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EDATREXATE; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; MELPHALAN; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PREDNISONE; TAXANE DERIVATIVE; THIOTEPA; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

BREAST CANCER; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CLASSIFICATION; DRUG EFFICACY; HISTORY OF MEDICINE; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034659774     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12+<3073::aid-cncr26>3.0.co;2-r     Document Type: Conference Paper

References (96)

1. Carter SK. Single and combination nonhormonal chemotherapy in breast cancer [review]. Cancer 1972;30:1543-55.
2. Henderson IC. Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC, Kinne DW, editors. Breast diseases. Philadelphia: J.B. Lippincott Company, 1991:604-65.
3. Greenspan EM. Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma. J Mt Sinai Hosp NY 1965;XXXII:1-27.
4. Greenspan EM, Feiber M, Lesnick G, Edelman S. Response of advanced breast carcinoma to the combination of the antimetabolite methotrexate and the alkylating agent thiotepa. J Mt Sinai Hosp NY 1963;30:246-67.
5. Cooper RG. Combination chemotherapy in hormone-resistant breast cancer [abstract]. Proc Am Assoc Cancer Res 1969;10:15.
6. Canellos GP, DeVita VT, Gold GL, Chabner BA, Schein PS, Young RC. Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Intern Med 1976;84:389-92.
7. O'Bryan RM, Luce JK, Talley RW, Gottlieb JA, Baker LH, Bonadonna G. Phase II evaluation of adriamycin in human neoplasia. Cancer 1973;32:1-8.
8. Ahmann DL, Bisel HF, Eagan RT, Edmonson JH, Hahn RG. Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. Cancer Chemother Rep 1974;58:877-82.
9. Bull JM, Tormey DC, Li SH, Carbone PP, Falkson G, Blom J, et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 1978;41: 1649-57.
10. Blumenschein GR, Cardenas JO, Freireich EJ, Gottlieb JA. FAC combination chemotherapy for metastatic breast cancer [abstract 839]. Proc Am Assoc Cancer Res 1974;15:193.
11. Buzdar AU, Gutterman JU, Blumenschein GR, Hortobagyi GN, Tashima CK, Smith TL, et al. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer 1978;41:1064-75.
12. Krutchik AN, Buzdar AU, Blumenschein GR, Hortobagyi GN, et al. Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. J Surg Oncol 1979; 11:325-32.
13. Hortobagyi GN, Blumenschein GR, Spanos W, Montague ED, Buzdar AU, Yap HY, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983;51: 763-8.
14. Fisher B, Redmond C, Wickerham DL, Bowman D, Schipper H, Wolmark N, et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 1989;7:572-82.
15. Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 [prior annotation incorrect]. J Clin Oncol 1990;8:1483-96.
16. Buzdar AU, Kau SW, Hortobagyi GN, Ames FC, Holmes FA, Fraschini G, et al. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer 1992; 69:448-52.
17. Hortobagyi GN, Buzdar AU. Present status of anthracyclines in the adjuvant treatment of breast cancer[review]. Drugs 1993;45:(Suppl2):10-9
18. Hutchins L, Green S, Ravdin P, Lew D, et al. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first resultsd of intergroup trial INT 0102 [abstract]. Proc Am Soc Clin Oncol 1998;17:1a.
19. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women [review]. J Clin Oncol 1998;16:3439-60.
20. A'Hern RP, Smith IE, Ebbs SR. Chemotherapy and survival in advanced breast cancer:the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993;67:801-5.
21. Fisher B, Ravdin RD, Ausman RK, Slack NH, Moore GE, Noer RJ. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 1968;168:337-56.
22. Fisher B. Systemic chemotherapy as an adjuvant to surgery in the treatment of breast cancer. Cancer 1969;24:1286-9.
23. Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, et al. L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med 1975;292:117-22.
24. Nissen-Meyer R, Host H, Kjellgren K, Mansson B, Norin T. Neoadjuvant chemotherapy in breast cancer: as single perioperative treatment and with supplementary long-term chemotherapy. In: Salmon SE, editor. Adjuvant therapy of cancer V. Orlando: Grune & Stratton, Inc., 1987:253-61.
25. Nissen-Meyer R, Kjellgren K, Mansson B. Preliminary report from the Scandinavian Adjuvant Chemotherapy Study Group. Cancer Chemother Rep 1971;55:561-6.
26. Carter SK, Rubens RD. Management of locally advanced and disseminated breast cancer. Lancet 1981;2:795-7.
27. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-42.
28. Early Breast Cancer Trialists' CollaborativeGroup. Treatment of early breast cancer. vol. 1. Worldwide evidence 1985-1990 [review]. Treatment of early breast cancer 1. New York: New York University Press. 1990:1-207
29. Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap HY, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979;39:1552-62.
30. Hryniuk WM, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-8.
31. Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988;6:1377-87.
32. Bissery M-C, Nohynek G, Sanderink G-J, Lavelle F. Docetaxel (taxotere): A review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 1995; 6:339-55.
33. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643-55.
34. O'Shaughnessy JA, Cowan KH. Current status of paclitaxel in the treatment of breast cancer. Breast Cancer Res Treat 1995;33:27-37.
35. Verweij J, Clavel M, Chevallier B. Paclitaxel (taxol) and docetaxel (taxotere): not simply two of a kind. Ann Oncol 1994;5:495-505.
36. Miller KD, Sledge GW Jr. Taxanes in the treatment of breast cancer: a prodigy comes of age [review] Cancer Invest 1999; 17:121-36.
37. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-94.
38. Ravdin PM, Burris HA III, Cook G, Eisenberg P, Kane M, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer [see comments]. J Clin Oncol 1995;13:2879-85.
39. Pivot X, Asmar L, Buzdar AU, Valero V, Hortobagyi G. A unified definition of clinical anthracycline-resistant breast cancer. Br J Cancer 2000;82:529-34.
40. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413-24.
41. Hortobagyi GN. Chemotherapy of breast cancer: a historical perspective [review]. Semin Oncol 1997;24:S17-1-4.
42. Hortobagyi GN. Recent progress in the clinical development of docetaxel (Taxotere) [review]. Semin Oncol 1999;26:32-6.
43. Hortobagyi GN, Holmes FA. Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer[review]. Semin Oncol 1997;24:S4-7.
44. Gelmon KA, O'Reilly SE, Tolcher AW, Campbell C, Bryce C, Ragaz J, et al. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996;14:1185-91.
45. Perez EA, Hartmann LC. Paclitaxel and carboplatin for advanced breast cancer[review]. Semin Oncol 1996;23:41-5.
46. Tolcher AW, Cowan KH, Noone MH, Denicoff AM, Kohler DR, Goldspiel BR, et al. Phase 1 study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol 1996;14:95-102.
47. Hortobagyi GN, Ibrahim N. Combinations of new and old agents for breast cancer treatment: future directions. Oncology 1996;10:30-6.
48. Klaassen U, Wilke H, Harstrick A, Seeber S. Fluorouracilbased combinations in the treatment of metastatic breast cancer. Oncology 1998;12:31-5.
49. Hainsworth JD, Jones SE, Mennel RG, Blum JL, Greco FA. Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: a phase II trial. J Clin Oncol 1996;14:1611-6.
50. Knick VC, Eberwein DJ, Miller CG. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 1995;87: 1072-7.
51. Hortobagyi GN. Paclitaxel-based combination chemotherapy for breast cancer. [Review] [54 refs]. Oncology 1997;11: 29-37.
52. Romero Acuna L, Langhi M, Perez J, et al. Vinorelbine (VNB) and paclitaxel (PTX) as first-line chemotherapy (FLC) in metastatic breast cancer (MBC) [meeting abstract]. Proc Annu Meet Am Soc Clin Oncol 1997;16:A661.
53. Khayat D, Antoine E. Docetaxel in combination chemotherapy for metastatic breast cancer [review]. Semin Oncol 1997; 24:S13-9-26.
54. Fumoleau P, Delacroix V, Perrocheau G, et al. Docetaxel in combination with vinorelbine as 1st line CT in pts with MBC: preliminary results on 22 entered Pts [abstract]. Breast Cancer Res Treat 1996;37:91.
55. Buzdar AU, Hortobagyi GN, Asmar L, Theriault RL, Rahman Z, McNeese M, et al. Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer. Semin Oncol 1997;24:S17-31-4.
56. Hortobagyi GN, Holmes FA, Ibrahim N, Champlin R, Buzdar AU. The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer [review]. Semin Oncol 1997;24:S30-3.
57. Henderson IC, Berry D, Demetri G, et al. Improved disease-free (DSF) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC) [abstract]. Proc Am Soc Clin Oncol 1998;17:101a.
58. Johnson SA, Harper P, Hortobagyi GN, Pouillart P. Vinorelbine: an overview. Cancer Treat Rev 1996;22:127-42.
59. Marty M, Extra JM, Dieras V, Giacchetti S, Ohana S, Espie M. A review of the antitumour activity of vinorelbine in breast cancer[review]. Drugs 1992;44:(Suppl)4:29-35.
60. Jabboury K, Holmes FA, Hortobagyi G. 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 1989;64:793-7.
61. Smith IE, Jones AL, O'Brien ME, McKinna JA, Sacks N, Baum M. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer [corrected and republished article originally printed in Eur J Cancer 1993;29A:592-51. Eur J Cancer 1993;29A:1796-9.
62. Cameron DA, Gabra H, Leonard RC. Continuous 5-fluorouracil in the treatment of breast cancer[review]. Br J Cancer 1994;70:120-4.
63. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17: 485-93.
64. Fischel JL, Etienne MC, Spector T, Formento P, Renee N, Milano G. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. Clin Cancer Res 1995;1: 991-6.
65. Diasio RB. Improving 5-FU with a novel dihydropyrimidine dehydrogenase inactivator. Oncology 1998;12:51-6.
66. Kaye SB. Gemcitabine: current status of phase I and II trials [editorial]. J Clin Oncol 1994;12:1527-31.
67. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation [review]. Semin Oncol 1995;22(Suppl 11):3-10
68. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995;13:2731-6.
69. Blackstein M, Vogel CL, Ambinder R, et al. Phase II study of gemcitabine in patients with metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1996;15:117.
70. Perez-Manga G, Lluch A, Garcia-Conde J, et al. High activity of gemcitabine with doxorubicin in advanced breast cancer: preliminary results from an early phase ii study. Abstracts of the Sixth International Congress on Anti-Cancer Treatment 1996;1:69.
71. Garcia-Conde J, Lluch A, Perez-Manga G, et al. Gemcitabine + doxorubicin in advanced breast cancer: final results from an early phase II study [meeting abstract]. Proc Annu Meet Am Soc Clin Oncol 1997;16:A515.
72. Luftner D, Flath B, Akrivakis C, Mergenthaler HG, Ohnmacht U, Arning M, et al. Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study. Invest New Drugs 1998;16:141-6.
73. Barnes DM, Gillett CE. Cyclin D1 in breast cancer [review]. Breast Cancer Res Treat 1998;52:1-15.
74. Jordan VC. Molecular biology of the estrogen receptor aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene [review]. Recent results. Cancer Res 1998;152:265-76.
75. Osborne CK. Steroid hormone receptors in breast cancer management [review]. Breast Cancer Res Treat 1998;51:227-38.
76. Killion JJ, Fidler IJ. The biology of tumor metastasis. Semin Oncol 1989;16:106-15.
77. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer [review]. Am J Clin Pathol 1999;112:S53-67
78. Gullick WJ, Srinivasan R. The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer [review]. Breast Cancer Res Treat 1998;52:43-53.
79. Hortobagyi GN, Hung M-C. The role of the HER-2 gene and its product in the management of primary and metastatic breast cancer. Perry MC, editor Alexandria, VA: American Society of Clinical Oncology. Fall Educational Book. 98. 1998:146-54.
80. Sliwkowski MX, Fox JA, Twaddell T. A humanized monoclonal antibody for the treatment of HER2 overexpressing breast cancer [meeting abstract]. Proc Annu Meet Am Assoc Cancer Res 1996;37:625-6.
81. Baselga J, Norton L, Coplan K, Shalaby R, Mendelsohn J. Antitumor activity of paclitaxel in combination with antigrowth factor receptor monoclonal antibodies in breast cancer xenografts [meeting abstract]. Proc Annu Meet Am Assoc Cancer Res 1994;35:380.
82. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31.
83. Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin™ (humanized anti-HER2 antibdy) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1998;17:97a.
84. Norton L, Slamon D, Leyland-Jones B, et al. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody Herceptin in HER2-overexpressing metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1999;18:127a.
85. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/ neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
86. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial [abstract]. Proc Am Soc Clin Oncol 1998;17:98a.
87. Workman P. Signal transduction inhibitors as novel anticancer drugs: where are we? Ann Oncol 1992;3:527-31.
88. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 1998;95:12022-7.
89. Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 1999;5:343-53.
90. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
91. Folkman J. Angiogenesis and breast cancer [editorial; comment]. J Clin Oncol 1994;12:441-3.
92. Teicher BA. Angiogenesis and cancer metastases: therapeutic approaches [review]. Crit Rev Oncol Hematol 1995;20:9-39.
93. Gastl G, Hermann T, Steurer M, Zmija J, Gunsilius E, Unger C, et al. Angiogenesis as a target for tumor treatment [review]. Oncology 1997;54:177-84.
94. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance [review]. Curr Opin Oncol 1995;7:541-6.
95. Seth P, Katayose D. Li Z, Kim M, Wersto R, Craig C, et al. A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: a gene therapy approach for drug-resistant cancers. Cancer Gene Ther 1997;4:383-90.
96. Disis ML, Cheever MA. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer [review]. Adv Cancer Res 1997;71:343-71.